| Bioactivity | CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into degenerative diseases of the central nervous system[1]. |
| CAS | 1185726-51-5 |
| Formula | C16H15ClN2O |
| Molar Mass | 286.76 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bey-Dih Chang, et al. Cdki pathway inhibitors and uses thereof. Patent, US20090281129. 2009-11-12. |
CDKI-IN-1
CAS: 1185726-51-5 F: C16H15ClN2O W: 286.76
CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into de
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.